MicroRNAs as Biomarkers of Pain Intensity in Patients With Chronic Fatigue Syndrome

Al-Rawaf, Hadeel A.; Alghadir, Ahmad H.; Gabr, Sami A.

doi:10.1111/papr.12817

Cited by 20 publications

(26 citation statements)

References 96 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-coding RNAs (ncRNA) control various levels of gene expression, chromatin architecture, epigenetic memory, transcription, RNA splicing, editing, and translation [ 160 ]. One specific type of ncRNA, the microRNAs (miRNA), alter and modulate several developmental, physiological, and pathophysiological processes [ 161 ]. This modulation can be achieved in different ways: by silencing genes, by initiating the cleavage of their respective target mRNA, or by inhibiting gene translation after complete or partial binding to their target sequence [ 162 ].…”

Section: Resultsmentioning

confidence: 99%

“…Low miR-199-3p expression, seen in ME/CFS subjects, is linked with poor survival outcomes in carcinomas, possibly affecting the disease-related physiological burden. Another dysregulated miR-223 modulates the TLR4/TLR2/NF-κB/STAT3 signaling pathway consequently affecting inflammatory cytokine expression [ 161 ]. The cytokines released in response to the inflammatory assault, particularly TNF-α, are directly suppressed by miR-130a-3p, reducing inflammation, and associated oxidative stress.…”

Section: Resultsmentioning

confidence: 99%

“…The overexpressed miR-4443 increases pro-inflammatory cytokines by activated the NF-κΒ pathway via targeting TRAF4. The expression of miR-558, miR-146a, miR-150, miR-124, and miR-143 associates directly with higher expression of immune inflammatory-related genes encoding TNF-α, IL-6, and COX-2 in adolescents with CFS [ 161 ]. In addition, NK cells have demonstrated the greatest changes in miRNA expression with upregulation of hsa-miR-99b and hsa-miR- 330-3p.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview

Deumer

Varesi

Floris

et al. 2021

JCM

View full text Add to dashboard Cite

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic systemic disease that manifests via various symptoms such as chronic fatigue, post-exertional malaise, and cognitive impairment described as “brain fog”. These symptoms often prevent patients from keeping up their pre-disease onset lifestyle, as extended periods of physical or mental activity become almost impossible. However, the disease presents heterogeneously with varying severity across patients. Therefore, consensus criteria have been designed to provide a diagnosis based on symptoms. To date, no biomarker-based tests or diagnoses are available, since the molecular changes observed also largely differ from patient to patient. In this review, we discuss the infectious, genetic, and hormonal components that may be involved in CFS pathogenesis, we scrutinize the role of gut microbiota in disease progression, we highlight the potential of non-coding RNA (ncRNA) for the development of diagnostic tools and briefly mention the possibility of SARS-CoV-2 infection causing CFS.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview

Deumer

Varesi

Floris

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Researchers and clinicians seem to agree on the urgent need for unbiased, specific diagnostic biomarkers for ME/ CFS to expedite patient diagnosis and treatment, and to abolish disease stigmas for good 45 . There is also a consensus on the advantages that miRNA profiles from different blood fractions, EVs included, exhibit as molecular diagnostic candidates, and yet, a paucity of studies focusing on ME/CFS miRNA profiling is detected 22,[24][25][26][27] .…”

Section: Discussionmentioning

confidence: 99%

Assessing diagnostic value of microRNAs from peripheral blood mononuclear cells and extracellular vesicles in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Almenar-Pérez

Sarría

Nathanson

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Myalgic encephalomyelitis/chronic fatigue Syndrome (Me/cfS) is a debilitating multisystemic disease of unknown etiology, affecting thousands of individuals worldwide. Its diagnosis still relies on ruling out medical problems leading to unexplained fatigue due to a complete lack of disease-specific biomarkers. Our group and others have explored the potential value of microRNA profiles (miRNomes) as diagnostic tools for this disease. However, heterogeneity of participants, low numbers, the variety of samples assayed, and other pre-analytical variables, have hampered the identification of diseaseassociated miRNomes. In this study, our team has evaluated, for the first time, ME/CFS miRNomes in peripheral blood mononuclear cells (pBMcs) and extracellular vesicles (eVs) from severely ill patients recruited at the monographic UK Me biobank to assess, using standard operating procedures (Sops), blood fractions with optimal diagnostic power for a rapid translation of a miR-based diagnostic method into the clinic. Our results show that routine creatine kinase (CK) blood values, plasma EVs physical characteristics (including counts, size and zeta-potential), and a limited number of differentially expressed PBMC and EV miRNAs appear significantly associated with severe ME/CFS (p < 0.05). Gene enrichment analysis points to epigenetic and neuroimmune dysregulated pathways, in agreement with previous reports. Population validation by a cost-effective approach limited to these few potentially discriminating variables is granted.Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease characterized by long-lasting (over 6 months) persistent debilitating widespread fatigue, which is exacerbated by exercise (post-exertional malaise or PEM), and not alleviated by rest 1-5 . It has been classified by the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) with code R53.82 or G93.3 if post-viral 6 . It affects at least 0.23 to 0.41% of the population worldwide 7,8 , although numbers can reach up to 5% depending on the diagnostic criteria and geographic locations, according to a recent revision by the EUROpean Myalgic Encephalomyelitis Network (EUROMENE) epidemiology working group 9 . The disease strikes people of all ages and within all socio-economic levels, being more common in women (female:male ratios between 2:1 and 6:1) 7-10 . ME/CFS is considered a life-long disabling disease, since only about 5% of patients return to their previous state of health 11 .The confusion among General Health Practitioners (GPs) due to multiple clinical definitions 12 and the large number of comorbidities, such as fibromyalgia, IBS (irritable bowel syndrome), POTS (postural orthostatic tachycardia syndrome), depression, etc, stigmatized the disease, delaying diagnosis and treatment of patients. This highlights the urgent need of unbiased, specific methods to diagnose ME/CFS in a clinical setting.

show abstract

“…2,8 Cellular oxidative stress was significantly associated with the severity of cognition impairment particularly in older adults with MCI. 32,[58][59][60][61][62] DNA damage (8-oxo-2ʹdeoxyguanosine; 8-oxodGuo), lipid peroxidation (malonaldehyde; MDA), and other cellular oxidative parameters significantly reported in higher ranges in the brain tissues, serum, plasma, and cerebrospinal fluid (CSF) patients with MCI. [58][59][60][61] In the current study, oxidative stress markers MDA and NO significantly increased, and CAT and SOD antioxidant defense activity significantly reduced in MCI compared to healthy-aged individuals.…”

Section: Discussionmentioning

confidence: 99%